AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: AZD1981
Drug: Placebo

First Posted Date: 2008-09-25

Last Posted Date: 2014-02-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 368

Registration Number: NCT00758589

Locations: 🇵🇱
Research Site, Wroclaw, Poland

Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment

Completed

Conditions: Schizophrenia

First Posted Date: 2008-09-25

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 80

Registration Number: NCT00758251

Locations: 🇱🇻
Research SIte, Cesis, Latvia
🇱🇻
Research Site, Valmiera, Latvia

A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: AZD1236

First Posted Date: 2008-09-25

Last Posted Date: 2015-04-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 55

Registration Number: NCT00758706

Locations: 🇳🇴
Research Site, Trondheim, Norway

Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Saxagliptin, 5 mg + insulin
Drug: Placebo + insulin

First Posted Date: 2008-09-23

Last Posted Date: 2015-06-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 455

Registration Number: NCT00757588

Locations: 🇺🇸
Clinical Research Advantage, Inc, Tempe, Arizona, United States
🇺🇸
Southgate Medical Group, West Seneca, New York, United States
🇺🇸
Valley Research, Fresno, California, United States

and more 14 locations

Treatment Clinical Practice in Bipolar Depression in Spain

Completed

Conditions: Bipolar Depression

First Posted Date: 2008-09-23

Last Posted Date: 2009-02-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 378

Registration Number: NCT00757328

Locations: 🇪🇸
Research Site, Valladolid, Spain

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: AZD9668
Drug: AZD9668 Placebo equivalent

First Posted Date: 2008-09-23

Last Posted Date: 2012-08-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 56

Registration Number: NCT00757848

Locations: 🇬🇧
Research Site, Liverpool, United Kingdom

AZD3355 Dose-escalation Study in Healthy Males

Phase 1

Completed

Conditions: Reflux Disease

Interventions: Drug: AZD3355
Drug: Placebo

First Posted Date: 2008-09-23

Last Posted Date: 2010-12-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 54

Registration Number: NCT00757419

Locations: 🇸🇪
Research Site, Gothenburg, Sweden

AZD8529 Single Ascending Dose Study

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: AZD8529
Drug: Placebo

First Posted Date: 2008-09-19

Last Posted Date: 2009-03-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 58

Registration Number: NCT00755378

Locations: 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AZD2516
Drug: Placebo

First Posted Date: 2008-09-18

Last Posted Date: 2008-12-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 72

Registration Number: NCT00754715

Locations: 🇸🇪
Research Site, Stockholm, Sweden

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: exenatide

First Posted Date: 2008-09-17

Last Posted Date: 2015-04-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 134

Registration Number: NCT00753896

Locations: 🇿🇦
Research Site, Pretoria, South Africa

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy